Can a Two-Drug combo outsmart Hard-to-Treat gynecological cancers?
NCT ID NCT07738757
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This phase II trial is testing whether combining two drugs—sacituzumab tirumotecan and tagitanlimab—can shrink tumors in people with advanced gynecological cancers (ovarian, endometrial, or cervical) that have a specific genetic feature called MSI-H/dMMR. Participants will receive both drugs intravenously every two weeks. The main goal is to see how many people respond to the treatment, with secondary goals of measuring survival and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan (Sac-TMT) combined with tagitanlimab (KL-A167)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced gynecological cancers that have not responded to prior therapies.
- What could go wrong
- This is an early-phase, single-arm trial, so results may not be conclusive. The combination may cause side effects and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC MSI-H/DMMR GYNECOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, 100730, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China